Pfizer's Lorbrena Shows 81% Reduction in Rare Lung Cancer Progression
TL;DR Summary
Pfizer's Lorbrena, a treatment for non-small cell lung cancer with specific genetic mutations, has shown an 81% reduction in cancer progression or death over five years in updated clinical trial data, significantly outperforming another Pfizer drug, Xalkori. Despite its impressive efficacy, Lorbrena's sales constitute only a small fraction of Pfizer's annual revenue.
- For one rare type of lung cancer, Pfizer pill reduces progression by 81% STAT
- Trial results for new lung cancer drug are ‘off the charts’, say doctors The Guardian
- Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancers NBC News
- Pfizer's drug for advanced lung cancer shows promising long-term trial results CNBC
- Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
81%
268 → 52 words
Want the full story? Read the original article
Read on STAT